JP2019521704A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521704A5
JP2019521704A5 JP2019516099A JP2019516099A JP2019521704A5 JP 2019521704 A5 JP2019521704 A5 JP 2019521704A5 JP 2019516099 A JP2019516099 A JP 2019516099A JP 2019516099 A JP2019516099 A JP 2019516099A JP 2019521704 A5 JP2019521704 A5 JP 2019521704A5
Authority
JP
Japan
Prior art keywords
seq
domain
nucleic acid
amino acid
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521704A (ja
JP7070932B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036178 external-priority patent/WO2017214167A1/en
Publication of JP2019521704A publication Critical patent/JP2019521704A/ja
Publication of JP2019521704A5 publication Critical patent/JP2019521704A5/ja
Application granted granted Critical
Publication of JP7070932B2 publication Critical patent/JP7070932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516099A 2016-06-06 2017-06-06 Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用 Active JP7070932B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346324P 2016-06-06 2016-06-06
US62/346,324 2016-06-06
US201662396767P 2016-09-19 2016-09-19
US62/396,767 2016-09-19
PCT/US2017/036178 WO2017214167A1 (en) 2016-06-06 2017-06-06 Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof

Publications (3)

Publication Number Publication Date
JP2019521704A JP2019521704A (ja) 2019-08-08
JP2019521704A5 true JP2019521704A5 (cg-RX-API-DMAC7.html) 2020-07-16
JP7070932B2 JP7070932B2 (ja) 2022-05-18

Family

ID=59071115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516099A Active JP7070932B2 (ja) 2016-06-06 2017-06-06 Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用

Country Status (10)

Country Link
US (3) US11161908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3464371A1 (cg-RX-API-DMAC7.html)
JP (1) JP7070932B2 (cg-RX-API-DMAC7.html)
KR (6) KR20250084978A (cg-RX-API-DMAC7.html)
CN (2) CN109311991B (cg-RX-API-DMAC7.html)
AU (2) AU2017277269C1 (cg-RX-API-DMAC7.html)
CA (1) CA3026640A1 (cg-RX-API-DMAC7.html)
IL (4) IL308798A (cg-RX-API-DMAC7.html)
SG (1) SG11201810887UA (cg-RX-API-DMAC7.html)
WO (1) WO2017214167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CA3026640A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CN112055595B (zh) 2018-01-22 2024-12-17 恩多塞特公司 Car t细胞的使用方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
EP3897720A4 (en) * 2018-12-19 2022-12-07 City of Hope BAFF-R BISPECIFIC T-LYMPHOCYTE ACTIVATING ANTIBODIES
JP7593646B2 (ja) * 2019-02-20 2024-12-03 シティ・オブ・ホープ Baff-r/cd19を標的としたキメラ抗原受容体修飾t細胞とその使用
US12023354B2 (en) 2019-05-31 2024-07-02 Case Western Reserve University Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
EP4041294A4 (en) * 2019-10-01 2024-10-02 Case Western Reserve University TARGETING B-CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) USING LIGAND-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN111499723B (zh) * 2020-05-28 2021-04-09 广州百暨基因科技有限公司 一种嵌合抗原受体及其应用
WO2022242710A1 (zh) * 2021-05-19 2022-11-24 上海诗健生物科技有限公司 一种特异性识别baff-r的嵌合抗原受体分子及其应用
JP2024528038A (ja) 2021-07-29 2024-07-26 ソノマ バイオセラピューティクス, インコーポレイテッド 調節性t細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体
CA3257911A1 (en) * 2022-06-01 2023-12-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant receptors binding to the B-cell activating factor receptor and their uses
CN116143943B (zh) * 2022-10-31 2023-09-01 邦恩泰(山东)生物医药科技集团股份有限公司 一种靶向baffr嵌合抗原受体、car-t细胞及应用
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
CN117050195B (zh) * 2023-10-13 2023-12-19 旭和(天津)医药科技有限公司 一种靶向baffr嵌合抗原受体、car-t细胞和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
MX2007008017A (es) * 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
WO2015164594A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
GB201412658D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
CA3026640A1 (en) 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof

Similar Documents

Publication Publication Date Title
JP2019521704A5 (cg-RX-API-DMAC7.html)
JP7390345B2 (ja) アゴニスト性tnf受容体結合物質
JP2020114264A5 (cg-RX-API-DMAC7.html)
JP2021177771A5 (cg-RX-API-DMAC7.html)
JP2018508215A5 (cg-RX-API-DMAC7.html)
JP2018508219A5 (cg-RX-API-DMAC7.html)
JP2019513394A5 (cg-RX-API-DMAC7.html)
JP2019511212A5 (cg-RX-API-DMAC7.html)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2019527557A5 (cg-RX-API-DMAC7.html)
JP2021087455A5 (cg-RX-API-DMAC7.html)
JP2020511136A5 (cg-RX-API-DMAC7.html)
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2018029594A5 (cg-RX-API-DMAC7.html)
JP2015527366A5 (cg-RX-API-DMAC7.html)
JP2017513478A5 (cg-RX-API-DMAC7.html)
JP2019515646A5 (cg-RX-API-DMAC7.html)
JP2016514457A5 (cg-RX-API-DMAC7.html)
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
JP2020513754A5 (cg-RX-API-DMAC7.html)
JP2019528769A5 (cg-RX-API-DMAC7.html)
JP2018172439A5 (cg-RX-API-DMAC7.html)
JP2015513920A5 (cg-RX-API-DMAC7.html)
JP2018532407A5 (cg-RX-API-DMAC7.html)
JP2017519502A5 (cg-RX-API-DMAC7.html)